newsfilter
← Latest News
GlobeNewswire·

NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology

  • NeOnc Technologies Holdings, Inc. will present data on its intranasal NEO100 & oral NEO212 programs at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia on November 13, 2026.
  • Poster CTNI-26 details durable radiographic remission & prolonged survival with NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma based on Phase 1/2a & compassionate use data.
  • Poster CTNI-27 covers Phase 1 safety, pharmacokinetics, & early activity signals for NEO212 in temozolomide-resistant recurrent glioblastoma & brain metastases.
  • NEO100 is an investigational intranasal perillyl alcohol delivery designed for non-invasive brain access, while NEO212 is an investigational oral conjugate of temozolomide & NEO100.
  • NEO212 has completed Phase 1 dose escalation & is advancing toward Phase 2 development under an FDA investigational new drug application.
  • NeOnc exclusively licenses a worldwide portfolio of issued patents & pending applications from the University of Southern California related to its drug candidates.